Mirataz (Mirtazapine)

Mirtazapine blocks central α2‑adrenergic receptors and antagonizes 5‑HT2 and 5‑HT3 serotonin receptors. By inhibiting these pathways, it releases norepinephrine and serotonin, neurotransmitters that promote hunger signals in the brain, leading to increased food intake and weight gain in cats.

The appropriate dose of Mirataz is determined by the prescribing veterinarian based on the cat’s weight, health status, and clinical response. Dosage regimens may vary, and owners should follow the specific instructions provided by the animal health professional.

Safety data for mirtazapine in pregnant or lactating cats are limited. Veterinarians generally exercise caution and weigh potential benefits against unknown risks. If use is considered essential, close monitoring and veterinary guidance are recommended.

To request Mirataz, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mirataz (mirtazapine) differs from older agents such as cyproheptadine by targeting both adrenergic and serotonergic pathways, often resulting in a more pronounced appetite boost with fewer anticholinergic side effects. Its safety profile and rapid onset make it a preferred choice for many veterinarians, though individual response can vary.

Mirataz should be stored at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed when not in use.

Mirataz is given orally, typically as a tablet or liquid formulation, according to the veterinarian’s instructions. It can be placed directly in the mouth or mixed with a small amount of food to ensure complete ingestion.

Serious adverse events, although rare, include severe hypersensitivity reactions (rash, facial swelling, anaphylaxis), neutropenia, hepatic dysfunction, seizures, and cardiac arrhythmias. Owners should seek immediate veterinary care if any of these signs appear.

Cats with a known hypersensitivity to mirtazapine or any of its excipients should not receive Mirataz. Additionally, animals with uncontrolled cardiac disease, severe liver impairment, or those receiving contraindicated serotonergic drugs should be evaluated carefully before use.